A Nomogram Based on Consolidation Tumor Ratio Combined with Solid or Micropapillary Patterns for Postoperative Recurrence in Pathological Stage IA Lung Adenocarcinoma.
consolidation tumor ratio
lung adenocarcinoma
nomogram
pathological subtype
prognosis
stage IA
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
14 Jul 2023
14 Jul 2023
Historique:
received:
18
06
2023
revised:
06
07
2023
accepted:
12
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Patients with pathological stage IA lung adenocarcinoma (LUAD) are at risk of relapse. The value of the TNM staging system is limited in predicting recurrence. Our study aimed to develop a precise recurrence prediction model for stage IA LUAD. Patients with pathological stage IA LUAD who received surgical treatment at Zhongshan Hospital Fudan University were retrospectively analyzed. Multivariate Cox proportional hazards regression models were used to create nomograms for recurrence-free survival (RFS). The predictive performance of the model was assessed using calibration plots and the concordance index (C-index). The multivariate Cox regression analysis revealed that CTR (0.75 < CTR ≤ 1; HR = 9.882, 95% CI: 2.036-47.959, We developed and validated a nomogram based on CTR and SMP patterns for predicting postoperative recurrence in pathological stage IA LUAD. This model is simple to operate and has better predictive performance than the eighth T stage system, making it suitable for selecting further adjuvant treatment and follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with pathological stage IA lung adenocarcinoma (LUAD) are at risk of relapse. The value of the TNM staging system is limited in predicting recurrence. Our study aimed to develop a precise recurrence prediction model for stage IA LUAD.
MATERIALS AND METHODS
METHODS
Patients with pathological stage IA LUAD who received surgical treatment at Zhongshan Hospital Fudan University were retrospectively analyzed. Multivariate Cox proportional hazards regression models were used to create nomograms for recurrence-free survival (RFS). The predictive performance of the model was assessed using calibration plots and the concordance index (C-index).
RESULTS
RESULTS
The multivariate Cox regression analysis revealed that CTR (0.75 < CTR ≤ 1; HR = 9.882, 95% CI: 2.036-47.959,
CONCLUSIONS
CONCLUSIONS
We developed and validated a nomogram based on CTR and SMP patterns for predicting postoperative recurrence in pathological stage IA LUAD. This model is simple to operate and has better predictive performance than the eighth T stage system, making it suitable for selecting further adjuvant treatment and follow-up.
Identifiants
pubmed: 37510119
pii: diagnostics13142376
doi: 10.3390/diagnostics13142376
pmc: PMC10378621
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the National Nature Science Foundation of China
ID : 82170110; 31400713
Organisme : the Shanghai Municipal Key Clinical Specialty
ID : shslczdzk02201
Organisme : the Shanghai Pujiang Program
ID : 20PJ1402400
Organisme : the Shanghai Engineer & Technology Research Center of Internet of Things for Respiratory Medicine
ID : 20DZ2254400
Références
Surg Oncol Clin N Am. 2016 Jul;25(3):447-68
pubmed: 27261908
J Thorac Oncol. 2015 Oct;10(10):1383-95
pubmed: 26295375
N Engl J Med. 2023 Feb 9;388(6):489-498
pubmed: 36780674
JTO Clin Res Rep. 2020 Nov 26;2(2):100126
pubmed: 34589986
Clin Lung Cancer. 2021 Jul;22(4):e574-e583
pubmed: 33234491
Cancer Imaging. 2020 Dec 12;20(1):87
pubmed: 33308323
Transl Cancer Res. 2021 Jun;10(6):2755-2766
pubmed: 35116586
Eur Radiol. 2018 Feb;28(2):747-759
pubmed: 28835992
Cancer Manag Res. 2020 Dec 07;12:12549-12556
pubmed: 33324099
Clin Lung Cancer. 2018 Jan;19(1):e47-e51
pubmed: 28743420
J Thorac Cardiovasc Surg. 2018 Mar;155(3):1227-1235.e2
pubmed: 29223834
Front Oncol. 2021 Apr 12;11:616149
pubmed: 33912445
BMC Cancer. 2020 Feb 24;20(1):150
pubmed: 32093621
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1193-9
pubmed: 24667022
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Lung Cancer. 2015 Nov;90(2):199-204
pubmed: 26341957
J Surg Oncol. 2022 Mar;125(4):796-808
pubmed: 34862621
J Thorac Oncol. 2016 Nov;11(11):1976-1983
pubmed: 27374456
Thorac Cancer. 2021 Jan;12(2):235-244
pubmed: 33231358
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Lancet. 2022 Apr 23;399(10335):1607-1617
pubmed: 35461558
J Thorac Oncol. 2010 Aug;5(8):1246-50
pubmed: 20559152
Chest. 2017 Feb;151(2):308-315
pubmed: 27435815
J Thorac Dis. 2017 Apr;9(4):1046-1053
pubmed: 28523159
Front Cell Dev Biol. 2021 Dec 08;9:769881
pubmed: 34957101
J Thorac Cardiovasc Surg. 2022 Jan;163(1):289-301.e2
pubmed: 33487427
Asian J Surg. 2022 Dec;45(12):2691-2699
pubmed: 35153141